Answers are grounded in this paper and cite their sources.
Gemcitabine-resistant pancreatic ductal adenocarcinoma (PDAC) can acquire an oxidative phosphorylation (OXPHOS)-high phenotype, creating a therapeutically exploitable vulnerability. Here, we developed compound 17, a triphenylphosphonium-conjugated CPI-613 derivative that suppresses pyruvate dehydrogenase complex (PDC) activity and mitochondrial respiration. By perturbing oxidative metabolism and redox homeostasis, 17 induced mitochondrial dysfunction and ferroptotic cell death, with PANC-1-GemR cells displaying greater sensitivity than parental PANC-1 cells. This selectivity translated in vivo: 17 outperformed gemcitabine in resistant xenografts and dose-dependently suppressed syngeneic Panc02 tumors. Compound 17 also attenuated EMT-associated phenotypes and hepatic metastatic burden without overt toxicity. These findings identify OXPHOS dependence as an actionable vulnerability in drug-resistant PDAC and position 17 as a promising mitochondria-targeted candidate for treating PDAC and limiting hepatic metastasis.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: